---
title: "688193.SH (688193.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688193.SH/news.md"
symbol: "688193.SH"
name: "688193.SH"
parent: "https://longbridge.com/en/quote/688193.SH.md"
datetime: "2026-03-11T10:45:29.644Z"
locales:
  - [en](https://longbridge.com/en/quote/688193.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688193.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688193.SH/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688193.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688193.SH/news.md)


# 688193.SH (688193.SH) — Related News

### [Rendu Biotechnology's net profit attributable to the parent company for the year 2025 is 9.5091 million yuan, turning a profit compared to the previous year's loss](https://longbridge.com/en/news/277218188.md)
*2026-02-27T14:56:03.000Z*
> Rendu Biotechnology released its performance report for the year 2025, with operating revenue of 162 million yuan, a yea

### [Rendu Biotechnology: Revenue of 162 million yuan in 2025, net profit increased by 17.3213 million yuan year-on-year](https://longbridge.com/en/news/277160044.md)
*2026-02-27T07:55:10.000Z*
> Rendu Biotechnology announced that the operating revenue for 2025 is expected to be 162 million yuan, a year-on-year dec

### [Rendu Biotechnology: Net profit of 2.038 million yuan in the first half of 2025, a year-on-year decrease of 52.94%](https://longbridge.com/en/news/255167860.md)
*2025-08-29T09:44:32.000Z*
> Rendu Biotechnology announced that in the first half of 2025, operating revenue was 81.2425 million yuan, a year-on-year

### [](https://longbridge.com/en/news/249323946.md)
*2025-07-21T02:25:51.000Z*
> The A-share monkeypox concept experienced a volatile rebound, with Yatai Pharm hitting the daily limit, Yipinhong reachi

### [Rendu Biotechnology obtained a medical device registration certificate](https://longbridge.com/en/news/242529916.md)
*2025-05-30T07:40:04.000Z*
> According to the Zhitong Finance APP, Rendu Biotechnology announced that its product, the Hepatitis B Virus Nucleic Acid

### [Rendu Biotechnology: The shareholding ratio of the controlling shareholder CCF has decreased to 4.99%](https://longbridge.com/en/news/239807064.md)
*2025-05-12T09:46:12.000Z*
> Rendu Biotechnology announced that its controlling shareholder and actual controller CENTRAL CHIEF LIMITED reduced its h

### [Rendu Biotechnology shareholder CENTRAL CHIEF LIMITED intends to inquire about the transfer of 1.25% of the company's shares](https://longbridge.com/en/news/238917918.md)
*2025-05-06T12:24:02.000Z*
> According to the Zhitong Finance APP, Rendu Biotechnology disclosed the shareholder inquiry transfer plan, with the part

### [Rendu Biotechnology's two innovative products selected for the Shanghai recommended catalog, accelerating the process of domestic substitution](https://longbridge.com/en/news/235735267.md)
*2025-04-13T06:01:45.000Z*
> Recently, the Shanghai Municipal Commission of Economy and Information Technology announced the second batch of the "Sha

### [Overview of the lifting of restrictions on the sale of A-shares by Zhitong | March 31](https://longbridge.com/en/news/233791381.md)
*2025-03-31T01:01:03.000Z*
> On March 31, 16 listed companies had their restricted shares unlocked, with a total market value of approximately 5.059 

### [Rendu Biotechnology's related products have obtained medical device registration certificates](https://longbridge.com/en/news/232923351.md)
*2025-03-24T08:07:04.000Z*
> According to the Zhitong Finance APP, Rendu Biotechnology announced that the company recently received the "Medical Devi